rly-4008,fgfr2 inhibitor
relay therapeutics,cogent biosciences
['fgfr2 inhibitor', 'rly-4008']
rly-4008, the first highly selective fgfr2 inhibitor with activity across fgfr2 alterations and resistance mutations #asco23 
Chief, Early-Phase Drug Development|@SarahCannonDocs
#Oncologist, #Phase1trials, #PrecisionMedicine. Tweets=My own.